The Impact of Environmental Factors on Thyroid Health: A Global Perspective

Alessandro Plebani^*
*Correspondence: Alessandro Plebani, Department of Clinical and Experimental Medicine, University of Pisa, Italy, Email:

Introduction

Hashimoto's thyroiditis and differentiated thyroid cancer are both common thyroid disorders that can coexist in the same individual. HT is an autoimmune condition characterized by chronic inflammation and destruction of the thyroid gland, leading to hypothyroidism in some cases. DTC, on the other hand, is a malignancy arising from thyroid follicular cells and includes papillary thyroid carcinoma and follicular thyroid carcinoma. The coexistence of HT with DTC presents unique challenges in the evaluation of treatment response and postoperative monitoring of anti-thyroglobulin antibodies. In this article, we discuss the clinical implications of this coexistence and strategies for managing these patients. The coexistence of HT with DTC is well-documented, with prevalence rates ranging from 20% to 60% in various studies. The presence of HT in DTC patients has been associated with a lower risk of lymph node metastasis and a better prognosis in some studies, although conflicting data exist. The autoimmune inflammation seen in HT may have a protective effect against the development and progression of DTC in some cases. The evaluation of treatment response in DTC patients with coexisting HT can be challenging due to the presence of TgAb, which can interfere with the measurement of serum thyroglobulin, a marker used for monitoring DTC recurrence. In patients with detectable TgAb, serum Tg levels may be falsely low or undetectable, making it difficult to assess treatment response. In such cases, alternative imaging modalities, such as neck ultrasound, may be used to monitor for recurrence [1].

Description

Monitoring of TgAb levels is crucial in DTC patients with coexisting HT to interpret serum Tg measurements accurately. Persistent or increasing TgAb levels post-operatively may indicate residual or recurrent disease, even in the presence of low or undetectable serum Tg levels. Serial monitoring of TgAb levels, along with imaging studies, can help assess treatment response and detect recurrence in these patients. Management of DTC in patients with coexisting HT requires a multidisciplinary approach involving endocrinologists, surgeons, and oncologists. Thyroid hormone replacement therapy is often necessary for patients with HT-related hypothyroidism, but the optimal management approach for DTC may vary depending on the individual patient's characteristics and disease course. Close monitoring of serum Tg levels, TgAb levels, and imaging studies is essential for early detection of recurrence and appropriate management. This coexistence necessitates careful evaluation, as the presence of HT can obscure the clinical presentation of DTC. For instance, thyroid nodules, which are common in both conditions, may complicate the differentiation between

Conclusion

3D culture models have been used to study various aspects of thyroid cancer biology, including tumor growth, invasion, and metastasis. They have also been used to screen for novel therapeutic agents and study drug resistance mechanisms. For example, 3D models have been used to identify potential therapeutic targets in thyroid cancer, such as the BRAFV600E mutation, which is found in a subset of PTCs and is associated with a poor prognosis. Despite their advantages, 3D culture models also present several challenges, including reproducibility, scalability, and the complexity of the microenvironment. Future research directions include the development of more sophisticated 3D models that better mimic the in vivo tumor microenvironment, as well as the integration of these models with other technologies such as imaging and omics analyses. Overall, 3D culture models have the potential to revolutionize thyroid cancer research and lead to the development of more effective therapies for this disease

References

Google Scholar, Crossref, Indexed at

Google Scholar, Crossref, Indexed at

1. Siegel, Rebecca L., Kimberly D. Miller and Ahmedin Jemal. "Cancer statistics, 2018." CA Cancer J Clin 68 (2018): 7-30.
2. Kitahara, Cari M. and Arthur B. Schneider. "Epidemiology of thyroid cancer." Cancer Epidemiol Biomarkers Prev 31 (2022): 1284-1297.